Robert Dee Etherington, the President and CEO of Clene Inc., has reported a significant acquisition of stock options, which may indicate his confidence in the company's future. Etherington acquired 55,000 stock options at an exercise price of $3.73 per share, as disclosed in a recent SEC filing.
This acquisition is noteworthy as it aligns Etherington's interests with those of shareholders, a common practice among executives in the pharmaceutical industry. The move reflects a strategic approach to enhance management's commitment to the company's performance.
Background
Clene Inc. operates in the pharmaceutical preparations sector, focusing on innovative therapies. The company is incorporated in Delaware and has a fiscal year ending on December 31. Its business address is located at 6550 South Millrock Drive, Suite G50, Salt Lake City, UT 84121. The company has been active in filing reports with the SEC, with the most recent filing being on October 21, 2026.
What the Filing Says
The SEC filing indicates that Etherington's stock options were granted on October 20, 2026, under the Clene Inc. Amended 2020 Stock Plan. These options will vest in 12 equal monthly installments starting on November 20, 2026. The filing states, "This option was granted as an option for 55,000 shares of Common Stock." Etherington now owns 55,000 shares following this transaction.
Impact
This acquisition may affect various stakeholders, including shareholders, employees, and potential investors. By acquiring these options, Etherington demonstrates a commitment to driving the company's success, which may enhance investor confidence and attract further interest in Clene Inc.'s stock.
What's Next
The filing does not say what happens next regarding Etherington's stock options or any future plans for Clene Inc.